4D Molecular Therapeutics, Inc. Announces Resignation of David Schaffer from Its Board of Directors and His Roles on the Nominating and Corporate Governance Committee and Science & Technology Committee

On February 17, 2022, David Schaffer, Ph.D. delivered notice of his resignation from the Board of Directors (the 'Board') of 4D Molecular Therapeutics, Inc. (the 'Company') including his roles on the Nominating and Corporate Governance Committee and Science & Technology Committee, effective immediately. Dr. Schaffer also conveyed notice of his intention to terminate his consulting agreement with the Company. Dr. Schaffer's resignation from the Board is not a result of a disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.